drugset
drugset / Trial / NCT03108495

Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma

NCT03108495 ↗

Phase 2 Terminated 210 enrolled Iovance Biotherapeutics, Inc.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

Prospective, multicenter, multiple cohort, open label, interventional study evaluating adoptive cell therapy (ACT) with autologous tumor infiltrating lymphocytes (TIL) infusion (LN-145), with or without pembrolizumab, followed by IL-2 after a non-myeloablative lymphodepletion (NMA-LD) preparative regimen for the treatment of participants with recurrent, metastatic, or persistent cervical carcinoma.

Timeline

Start
2017-06-22
Primary completion
2025-08-22
Completion
2025-08-22

Outcome

Outcome not reported

Stopped: “After reviewing available safety and efficacy data to date, Iovance concluded the study reached the required number of events for evaluation of study endpoints.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Pembrolizumab Monoclonal antibody — —
Subject Tumor Infiltrating Lymphocytes Cell therapy — —

Indications

cervical carcinoma